Recent Event
16th Annual LD Micro Main Event
Company Overview
Skye is a pharmaceutical company unlocking the pharmaceutical potential of the endocannabinoid system, initially with a focus on modulating the CB1 receptor, through the development of proprietary molecules to treat diseases with inflammatory, fibrotic, and metabolic disease processes. Skye’s first-in-class and only-in-class SBI-100 Ophthalmic Emulsion is focused on developing a treatment for glaucoma, the world’s leading cause of irreversible blindness. Nimacimab is a first-in-class and only-in-class Phase 2-ready, negative allosteric modulator antibody focused on CB1 inhibition and is being developed to potentially treat with fibrotic, inflammatory and metabolic-related diseases with significant prevalence and unmet need.
IR Contacts
Company
Skye Bioscience, Inc.
11250 El Camino Real
Suite 100
San Diego, CA 92130
Investor Relations
SKYE Investor Relations
T: (858) 410-0266
ir@skyebioscience.com
Transfer Agent
ClearTrust, LLC
16540 Pointe Village Dr.
Suite 210
Lutz, FL 33558
T: 813-235-4490
www.ClearTrustOnline.com
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.